Thorax 2000;55:478-483 ( June )

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials

Neil C Barnes^a, Christopher J Miller^b

^a Department of Respiratory Medicine, The London Chest Hospital, London E2 9JX, UK, ^b AstraZeneca, Wilmington, Delaware, USA

Correspondence to: Dr N C Barnes

Received 6 May 1999; Returned to authors 18 June 1999; Revised version received 10 February 2000; Accepted for publication 1 March 2000

BACKGROUNDAsthma exacerbations contribute substantially to morbidity, and their reduction is an important therapeutic objective. In this integrated analysis the risk of asthma exacerbations was assessed during treatment with the leukotriene receptor antagonist zafirlukast.
METHODSData were collected from all five double blind, multicentre, randomised, placebo controlled, 13 week trials of zafirlukast 20 mg twice daily performed in steroid-naive patients with mild to moderate asthma. Exacerbation data were collected prospectively during monitoring of adverse events and concomitant medication use. Pooled data were used to assess the relative risk of asthma exacerbations using three definitions: worsening of asthma leading to withdrawal from the study; requirement for additional anti-asthma therapy (excluding increased short acting ₂ agonist use); and requirement for oral corticosteroid therapy.
RESULTSThe proportion of patients with an asthma exacerbation leading to withdrawal was consistently lower in the group treated with zafirlukast 20 mg twice daily than in the placebo group. Overall, the risk of an asthma exacerbation requiring withdrawal from zafirlukast therapy was approximately half that of placebo (odds ratio 0.45; 95% CI 0.26 to 0.76; p = 0.003). Similar results were observed for exacerbations requiring additional control medication (odds ratio = 0.47; 95% CI 0.30 to 0.74; p = 0.001) and oral corticosteroid rescue (odds ratio = 0.53; 95% CI 0.32 to 0.86; p = 0.010).
CONCLUSIONSZafirlukast in a dose of 20 mg twice daily reduces the risk of asthma exacerbations and the need for additional anti-asthma therapies, fulfilling an important goal of control medication in patients with mild to moderate asthma.


Keywords: asthma; zafirlukast; leukotriene receptor antagonist

---

© 2000 by Thorax
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., de Jongste, J. C., Kerstjens, H. A. M., Lazarus, S. C., Levy, M. L., O'Byrne, P. M., Partridge, M. R., Pavord, I. D., Sears, M. R., Sterk, P. J., Stoloff, S. W., Sullivan, S. D., Szefler, S. J., Thomas, M. D., Wenzel, S. E., on behalf of the American Thoracic Society/Europea, (2009). An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice. Am. J. Respir. Crit. Care Med. 180: 59-99 [Abstract] [Full Text]  
• Sykes, A., Seemungal, T., ICEAD contributors, (2008). Recent advances in exacerbations of asthma. Thorax 63: 758-760 [Full Text]  
• Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., Pizzichini, E., Sullivan, S. D., Wenzel, S. E., Zar, H. J. (2008). Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31: 143-178 [Abstract] [Full Text]  
• Jayaram, L, Pizzichini, E, Lemiere, C, Man, S F P, Cartier, A, Hargreave, F E, Pizzichini, M M M (2005). Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax 60: 100-105 [Abstract] [Full Text]  
• Silverman, R. A., Nowak, R. M., Korenblat, P. E., Skobeloff, E., Chen, Y., Bonuccelli, C. M., Miller, C. J., Simonson, S. G. (2004). Zafirlukast Treatment for Acute Asthma: Evaluation in a Randomized, Double-Blind, Multicenter Trial. Chest 126: 1480-1489 [Abstract] [Full Text]  
• Currie, G. P., Lipworth, B. J. (2002). Bronchoprotective Effects of Leukotriene Receptor Antagonists in Asthma* : A Meta-analysis. Chest 122: 146-150 [Abstract] [Full Text]  
• Minoguchi, K., Kohno, Y., Minoguchi, H., Kihara, N., Sano, Y., Yasuhara, H., Adachi, M. (2002). Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast. Chest 121: 732-738 [Abstract] [Full Text]